Foundations · Year 1 · from Foundations
Case 3: Chronic Myelogenous Leukemia (CDK4/6 Inhibitor Therapy Concept)
Clinical Image
Source: Wikipedia - Philadelphia chromosome - CC BY-SA 3.0
Case Presentation
A 58-year-old woman with metastatic hormone receptor-positive (HR+), HER2-negative breast cancer is started on palbociclib (a CDK4/6 inhibitor) in combination with letrozole (an aromatase inhibitor). Her oncologist explains the mechanism: estrogen receptor signaling drives cyclin D expression in HR+ breast cancer, which activates CDK4/6 to phosphorylate Rb, releasing E2F and promoting proliferation. Palbociclib inhibits CDK4/6, blocking Rb phosphorylation and causing G1 arrest. Combining CDK4/6 inhibition with estrogen deprivation (aromatase inhibitor) provides synergistic cell cycle blockade. She is counseled that the main side effect is neutropenia (low neutrophil counts), requiring regular blood count monitoring. The physician notes that CDK4/6 inhibitors only work when Rb is intact; tumors that have lost Rb cannot respond because the downstream pathway is already derepressed. She asks why this drug helps breast cancer but not other cancers. The physician explains that HR+ breast cancer is particularly dependent on cyclin D-CDK4/6 pathway for proliferation, making it an ideal target. Her disease shows excellent response, with progression-free survival extended significantly compared to hormonal therapy alone.
Key Learning Points
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) block the kinases that phosphorylate Rb, preventing E2F release and causing G1 arrest; they require functional Rb to be effective
- These drugs are approved for HR+ breast cancer because this tumor type is particularly dependent on cyclin D-CDK4/6-Rb pathway driven by estrogen receptor signaling
- Understanding cell cycle regulation has enabled development of targeted therapies; the cell cycle checkpoints and their regulators are important therapeutic targets in oncology